Substance use disorder affects people across age groups and settings, shaped by co-occurring mental illness, physical health, and access to timely care. This page walks through what the data show in the U.S. and globally, from prevalence and substance use patterns to overdoses and preventable deaths. You’ll also see how treatment gaps and evidence-based care help influence outcomes like retention and mortality.
Key Takeaways
- In 2021, 1 in 4 U.S. adults with mental illness did not receive needed treatment; co-occurring SUD increases this unmet need to 1 in 3 (unmet need rates reported in SAMHSA analysis).
- Significantly more people received MOUD when offered immediately after overdose: 45% initiated buprenorphine/naloxone within 30 days vs 5% with delayed or no offer in an RCT (initiation within 30 days).
- MAT retention was higher with monthly extended-release buprenorphine vs daily sublingual: 48% vs 26% stayed in treatment at 12 weeks in a randomized trial (retention at 12 weeks).
- 30.4% of adults in the United States reported binge drinking at least once in 2020 (percentage reporting binge drinking in the past month).
- 15.5% of U.S. adults reported using illicit drugs in the past month in 2019 (percentage of adults reporting past-month illicit drug use).
- 1.6 million U.S. adults had opioid use disorder in 2019 (estimated number of adults with opioid use disorder).
- 80,411 opioid-involved overdose deaths occurred in the United States in 2020 (number of opioid-involved overdose deaths).
- 12.5% of U.S. adults aged 18–25 had SUD in 2022 (percentage by age group).
- 2.6x higher risk of all-cause mortality for patients with opioid use disorder vs. controls (hazard ratio reported in a large cohort study).
- Over 2,000,000 people received treatment with medications for opioid use disorder (MOUD) through substance use treatment programs in the U.S. in 2021 (number receiving MOUD in specialty facilities).
- $0.9 billion (2019) was spent by Medicare on substance use disorder treatment in the United States (Medicare payer expenditures).
- Only 15% of people with opioid use disorder worldwide received opioid agonist therapy in 2021 (treatment coverage percentage).
- $14.4 billion in state Medicaid expenditures were associated with substance use disorder services in 2018 (Medicaid spending on SUD).
- The National Institutes of Health funded $1.8 billion in awards related to substance use disorder research in FY2023 (NIH grant totals for substance use disorder research areas, NIH RePORTER).
- $5.0 billion was allocated to the State Targeted Response (STR) for opioid use disorder between 2017 and 2018 (grant allocation amount).
From unmet need to better outcomes, prompt medication and treatment for substance use disorders can save lives.
Related reading
01 · Category
Treatment Access12 stats
01
In 2021, 1 in 4 U.S. adults with mental illness did not receive needed treatment; co-occurring SUD increases this unmet need to 1 in 3 (unmet need rates reported in SAMHSA analysis).
02
Significantly more people received MOUD when offered immediately after overdose: 45% initiated buprenorphine/naloxone within 30 days vs 5% with delayed or no offer in an RCT (initiation within 30 days).
03
MAT retention was higher with monthly extended-release buprenorphine vs daily sublingual: 48% vs 26% stayed in treatment at 12 weeks in a randomized trial (retention at 12 weeks).
04
Opioid use disorder: 43% reduction in mortality with methadone treatment vs no methadone (relative risk reduction reported in a systematic review).
05
80% of U.S. people with opioid use disorder can access naloxone within 1 mile in major metropolitan areas in 2022 (share of people with nearby access, modeled).
06
In the United States, 71.5% of county residents live within a 2-hour drive of an opioid treatment program (access modeled by SAMHSA program directory analysis).
07
26.3% of U.S. adults with mental illness who also have co-occurring substance use disorder reported unmet need for treatment in 2022
08
35.7% of U.S. adults with mental illness who also have co-occurring substance use disorder reported unmet need for treatment in 2022
09
19.9% of U.S. adults with mental illness who do not have co-occurring substance use disorder reported unmet need for treatment in 2022
10
26.8% of U.S. adults with mental illness who do not have co-occurring substance use disorder reported unmet need for treatment in 2022
11
26.3% of U.S. adults with mental illness who also have co-occurring substance use disorder had unmet need for mental health treatment in 2022
12
19.9% of U.S. adults with mental illness who do not have co-occurring substance use disorder had unmet need for mental health treatment in 2022
Interpretation
Treatment Access Interpretation
For treatment access, the data show that while access and engagement can dramatically improve outcomes such as starting MOUD after overdose (45% within 30 days versus 5%) and better retention with monthly extended-release buprenorphine (48% versus 26% at 12 weeks), unmet treatment needs remain high with co-occurring SUD raising the gap for adults with mental illness to 1 in 3 who do not receive needed care.
report visual · Comparison
Unmet mental health treatment need is higher with co-occurring SUD
In 2022, adults with co-occurring substance use disorder reported a higher unmet need for mental health treatment than those without co-occurring SUD, leading the gap by 26.3% vs 1
26.3% of U.S. adults with mental illness who also have co-occurring substance use disorder had unmet need for mental hea26.3%
26.3% of U.S. adults with mental illness who also have co-occurring substance use disorder reported unmet need for treat
26.3%
19.9% of U.S. adults with mental illness who do not have co-occurring substance use disorder had unmet need for mental h
19.9%
source-verifiedsamhsa.gov2022
02 · Category
Epidemiology4 stats
01
30.4% of adults in the United States reported binge drinking at least once in 2020 (percentage reporting binge drinking in the past month).
02
15.5% of U.S. adults reported using illicit drugs in the past month in 2019 (percentage of adults reporting past-month illicit drug use).
03
1.6 million U.S. adults had opioid use disorder in 2019 (estimated number of adults with opioid use disorder).
04
3.6% of global deaths were attributable to substance use and illicit drug use in 2019 (fraction of total deaths).
Interpretation
Epidemiology Interpretation
From an epidemiology standpoint, substance use is widespread and affects millions, with 30.4% of U.S. adults reporting binge drinking in 2020, 15.5% reporting past-month illicit drug use in 2019, and about 1.6 million U.S. adults estimated to have opioid use disorder in 2019, while globally 3.6% of all deaths were attributable to substance and illicit drug use in 2019.
03 · Category
Mortality & Morbidity4 stats
01
80,411 opioid-involved overdose deaths occurred in the United States in 2020 (number of opioid-involved overdose deaths).
02
12.5% of U.S. adults aged 18–25 had SUD in 2022 (percentage by age group).
03
2.6x higher risk of all-cause mortality for patients with opioid use disorder vs. controls (hazard ratio reported in a large cohort study).
04
2,465,503 overdose deaths prevented by naloxone distribution programs in the United States between 1996 and 2019 (estimated overdose reversals).
Interpretation
Mortality & Morbidity Interpretation
Mortality and morbidity from substance use disorders remain severe, with 80,411 opioid-involved overdose deaths in the United States in 2020 and evidence that opioid use disorder carries a 2.6 times higher risk of all-cause mortality, even as naloxone distribution programs helped prevent an estimated 2,465,503 overdose deaths between 1996 and 2019.
More related reading
04 · Category
Market & Services4 stats
01
Over 2,000,000 people received treatment with medications for opioid use disorder (MOUD) through substance use treatment programs in the U.S. in 2021 (number receiving MOUD in specialty facilities).
02
$0.9 billion (2019) was spent by Medicare on substance use disorder treatment in the United States (Medicare payer expenditures).
03
Only 15% of people with opioid use disorder worldwide received opioid agonist therapy in 2021 (treatment coverage percentage).
04
In 2022, there were 15,000+ clinicians registered to prescribe buprenorphine in the U.S. (count of providers by registration program).
Interpretation
Market & Services Interpretation
For the Market & Services angle, treatment access and capacity remain limited despite scale, with over 2,000,000 people receiving MOUD through U.S. programs and Medicare spending $0.9 billion in 2019, yet only 15% of people with opioid use disorder worldwide getting opioid agonist therapy in 2021 and just 15,000+ U.S. clinicians registered to prescribe buprenorphine in 2022.
05 · Category
Policy & Funding7 stats
01
$14.4 billion in state Medicaid expenditures were associated with substance use disorder services in 2018 (Medicaid spending on SUD).
02
The National Institutes of Health funded $1.8 billion in awards related to substance use disorder research in FY2023 (NIH grant totals for substance use disorder research areas, NIH RePORTER).
03
$5.0 billion was allocated to the State Targeted Response (STR) for opioid use disorder between 2017 and 2018 (grant allocation amount).
04
The SAMHSA “Behavioral Health Barometer” reported 4,000+ grants awarded for substance use prevention and treatment between 2020 and 2023 (grant count).
05
In FY2022, the Substance Abuse and Mental Health Services Administration (SAMHSA) budget included $6.9 billion for behavioral health programs (agency total).
06
The 2021–2022 HHS opioid response package included $3.6 billion for treatment, prevention, and recovery (HHS investment amount).
07
The 21st Century Cures Act included $1.5 billion for opioid and behavioral health programs over several years (law-related funding authorization).
Interpretation
Policy & Funding Interpretation
Across major federal and state funding streams, investment in substance use disorder has been substantial and sustained, with 2018 Medicaid spending totaling $14.4 billion, $1.8 billion in NIH research awards in FY2023, and $3.6 billion from the 2021 to 2022 HHS opioid response package, underscoring that policy and funding are central to scaling treatment, prevention, and recovery efforts.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
James Okoro. (2026, February 13). Substance Use Disorder Statistics. Gitnux. https://gitnux.org/substance-use-disorder-statistics
MLA
James Okoro. "Substance Use Disorder Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/substance-use-disorder-statistics.
Chicago
James Okoro. 2026. "Substance Use Disorder Statistics." Gitnux. https://gitnux.org/substance-use-disorder-statistics.
Sources & references
26 datasets cited across this report · attribution is report-level
+15 additional datasets cited (not shown individually)